Strata Critical Medical Inc (SRTA) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Strata Critical Medical Inc   (NASDAQ: SRTA)

Select the Financial Report: Select the Period:


Description of Strata Critical Medical Inc's Business Segments


Strata operates two reportable business segments: Logistics and Clinical. The Logistics segment, marketed under the Trinity brand, comprises Air Logistics, which involves air transportation of human organs and related items using fixed-wing aircraft and commercial flights with on-board couriers; Ground Logistics, which covers ground transportation of human organs and related items; and Organ Placement, which provides administrative services for donor organ acceptance and transplant coordination. The Clinical segment, marketed under the Keystone brand, includes Transplant Clinical services such as Organ Recovery, involving surgical procurement of donor organs; Normothermic Regional Perfusion (NRP) to improve organ outcomes; and Preservation, which operates devices to preserve organs. Additional Clinical services include Cardiac Care, encompassing cardiac perfusion, blood management, autotransfusion, and disposables under hospital contracts, as well as services like Extracorporeal Membrane Oxygenation (ECMO), perfusion temporary staffing, and equipment rental. Strata's Logistics segment operates on a contractual basis with transplant centers and related organizations, utilizing an asset-light air logistics model that primarily relies on third-party owned and operated aircraft. Costs are borne by operators, with fixed hourly rates negotiated to establish a predictable cost structure. Capacity purchase agreements provide guaranteed flight commitments and dedicated aircraft access.


Composition of Strata Critical Medical Inc Revenues by Segments

 
Logistics    132.18 % of total Revenue
Clinical    60.75 % of total Revenue

Q2 three months ended (Jun 30 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Logistics 95.84 132.18 %
Clinical 44.05 60.75 %
Total 72.51 100 %




Q2 three months ended (Jun 30 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Logistics - 101.35 %
Clinical - 122.65 %
Total - 8.03 %




Q2 three months ended (Jun 30 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -10.52 -




Q2 three months ended (Jun 30 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Strata Critical Medical Inc Divisions, Sales by Country

 
Logistics   Logistics Segment contribution to total sales 89.69 % of total Revenue
Clinical   Clinical Segment contribution to total sales 10.32 % of total Revenue
Clinical Transplant clinical   Clinical Transplant clinical Segment contribution to total sales 4.55 % of total Revenue
Clinical Other clinical   Clinical Other clinical Segment contribution to total sales 5.77 % of total Revenue


Twelve months ended 2025
SRTA s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Logistics 176.79 89.69 %
Clinical 20.35 10.32 %
Total 197.13 100 %
Clinical Transplant clinical 8.96 4.55 %
Clinical Other clinical 11.38 5.77 %


Twelve months ended 2025
SRTA s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Logistics 36.63 20.72 %
Clinical 4.50 22.09 %
Total 41.35 20.97 %

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Logistics 20.42 % 23.8 %



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.